A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: A randomised, double-blind, placebo-controlled proof-of-concept clinical trial

BMJ Open

Volumn 3, Issue 4, 2013, Pages

  Pantzaris, Marios C ^a   Loukaides, George N ^a   Ntzani, Evangelia E ^b   Patrikios, Ioannis S ^a,c  

^a CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^b UNIVERSITY OF IOANNINA   (Greece)

^c EUROPEAN UNIVERSITY CYPRUS   (Cyprus)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; DOCOSAHEXAENOIC ACID; GAMMA LINOLENIC ACID; GAMMA TOCOPHEROL; ICOSAPENTAENOIC ACID; LINOLEIC ACID; MONOUNSATURATED FATTY ACID; NUTRACEUTICAL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PLACEBO; POLYUNSATURATED FATTY ACID; RETINOL; SATURATED FATTY ACID;

ADULT; ADVERSE OUTCOME; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SCORING SYSTEM; TREATMENT DURATION;

EID: 84877698744     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-002170     Document Type: Article

References (61)

1. Baranzini SE, Oksenberg JR, Hauser SL. New insights into the genetics of multiple sclerosis. J Rehabil Res Dev 2002;39:201-10. (Pubitemid 34627419)
2. Goni J, Esteban FJ, De Mendizabal NV, et al. A computational analysis of protein-protein interaction networks in neurodegenerative diseases. BMC Syst Biol 2008;2:52.
3. Lobo I. Multifactorial inheritance and genetic disease. Nat Educ 2008;1(1) http://www.nature.com/scitable/topicpage/multifactorial-inheritance- and-genetic-disease-919.
4. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221.
5. Evans PH. Free radicals in brain metabolism and pathology. Br Med Bull 1993;49:577-87. (Pubitemid 23243831)
6. Knight J. Reactive oxygen species and the neurodegenerative disorders. Ann Clin Lab Sci 1997;27:11-25. (Pubitemid 27030199)
7. Matute C, Alberdi E, Domercq M, et al. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci 2001;24:224-30. (Pubitemid 32204379)
8. Owens T. The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr Opin Neurol 2003;16:259-65. (Pubitemid 36688291)
9. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 1999;9:69-92. (Pubitemid 29056521)
10. Ahn AC, Tewari M, Poon CS, et al. The clinical applications of a systems approach. PLoS Med 2006;3:e209.
11. Auffray C, Chen Z, Hood L. Systems medicine: the future of medical genomics and healthcare. Genome Med 2009;1:2.
12. Van Meeteren ME, Teunissen CE, Dijkstra CD, et al. Antioxidants and polyunsaturated fatty acids in multiple sclerosis. Eur J Clin Nutr 2005;59:1347-61. (Pubitemid 43135149)
13. Cunnane S, Ho S, Dore-Duffy P, et al. Essential fatty acid and lipid profiles in plasma and erythrocytes in patients with multiple sclerosis. Am J Clin Nutr 1989;50:801-6. (Pubitemid 19252739)
14. Harbige LS, Pinto E, Xiang M, et al. Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis. Proc Nutr Soc 2008;67:E21. (Pubitemid 351988231)
15. Wilson R, Tocher D. Lipid and fatty acid composition is altered in plaque tissue from multiple sclerosis brain compared with normal brain white matter. Lipids 1991;26:9-15.
16. Calder PC. n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83:S1505-19.
17. Piani D, Fontana A. Involvement of the cystine transport system xc-in the macrophage-induced glutamate-dependent cytotoxicity to neurons. J Immunol 1994;152:3578-85.
18. Youdim KA, Martin A, Joseph JA. Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci 2000;18:383-99. (Pubitemid 30244351)
19. Calder PC. Dietary modification of inflammation with lipids. Proc Nutr Soc 2002;61:345-58. (Pubitemid 34982924)
20. Gil Á. Polyunsaturated fatty acids and inflammatory diseases. Biomed Pharmacother 2002;56:388-96. (Pubitemid 35232741)
21. Ariel A, Serhan CN. Resolvins and protectins in the termination program of acute inflammation. Trends Immunol 2007;28:176-83. (Pubitemid 46467520)
22. Arita M, Ohira T, Sun YP, et al. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and chemR23 to regulate inflammation. J Immunol 2007;178:3912-17. (Pubitemid 46417661)
23. Janakiram NB, Rao CV. Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer. Curr Mol Med 2009;9:565-79.
24. Serhan C, Arita M, Hong S, et al. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids 2004;39:1125-32. (Pubitemid 40129055)
25. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349-61. (Pubitemid 351595216)
26. Rossetti RG, Seiler C, DeLuca P, et al. Oral administration of unsaturated fatty acids: effects on human peripheral blood T lymphocyte proliferation. J Leukoc Biol 1997;62:438-43. (Pubitemid 27459771)
27. Vatassery G. Vitamin E and other endogenous antioxidants in the central nervous system. Geriatrics 1998a;53(Suppl 1):S25-7.
28. Fukuzawa K, Gebicki JM. Oxidation of [alpha]-tocopherol in micelles and liposomes by the hydroxyl, perhydroxyl, and superoxide free radicals. Arch Biochem Biophys 1983;226:242-51. (Pubitemid 13022195)
29. Christen S, Woodall AA, Shigenaga MK, et al. γ-Tocopherol traps mutagenic electrophiles such as NOx and complements α-tocopherol: physiological implications. Proc Natl Acad Sci USA 1997;94:3217-22.
30. Brigelius-Flohé R, Kelly FJ, Salonen JT, et al. The European perspective on vitamin E: current knowledge and future research. Am J Clin Nutr 2002;76:703-16.
31. Calder P. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases Mol. Nutr Food Res 2008;52:885-97.
32. Edwards IJ, O'Flaherty JT. Omega-3 fatty acids and PPARγ in cancer. PPAR Res 2008;2008:1-15.
33. Groeger AL, Cipollina C, Cole MP, et al. Cyclooxygenase-2 generates anti-inflammatory mediators from omega-3 fatty acids. Nat Chem Biol 2010;6:433-41.
34. Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol 2008;9:162-76. (Pubitemid 351158917)
35. Dyall SC, Michael GJ, Michael-Titus AT. Omega-3 fatty acids reverse age-related decreases in nuclear receptors and increase neurogenesis in old rats. J Neurosci Res 2010; 88:2091-102.
36. Salvati S, Natali F, Attorri L, et al. Eicosapentaenoic acid stimulates the expression of myelin proteins in rat brain. J Neurosci Res 2008;86:776-84. (Pubitemid 351357759)
37. Abraham M, Shapiro S, Karni A, et al. Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J Neuroimmunol 2005;163:157-64. (Pubitemid 40692958)
38. Ffrench-Constant C. Pathogenesis of multiple sclerosis. Lancet 1994;343:271-75. (Pubitemid 24039632)
39. Leppert D, Lindberg RLP, Kappos L, et al. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Rev 2001;36:249-57. (Pubitemid 33020755)
40. Curtis CL, Rees SG, Cramp J, et al. Effects of n-3 fatty acids on cartilage metabolism. Proc Nutr Soc 2002;61:381-9. (Pubitemid 34982929)
41. Harris MA, Hansen RA, Vidsudhiphan P, et al. Effects of conjugated linoleic acids and docosahexaenoic acid on rat liver and reproductive tissue fatty acids, prostaglandins and matrix metalloproteinase production. Prostaglandins Leukot Essent Fatty Acids 2001;65:23-9. (Pubitemid 32783438)
42. McCabe A, Wallace J, Gilmore W, et al. The effect of eicosapentanoic acid on matrix metalloproteinase gene expression. Lipids 1999;34:S217-18.
43. Shinto L, Marracci G, Bumgarner L, et al. The effects of Omega-3 fatty acids on matrix metalloproteinase-9 production and cell migration in human immune cells: implications for multiple sclerosis. Autoimmune Dis 2011;2011:1-6.
44. McNamara RK. DHA deficiency and prefrontal cortex neuropathology in recurrent affective disorders. J Nutr2010;140:864-8.
45. Huang WL, King VR, Curran OE, et al. A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury. Brain 2007;130:3004-19. (Pubitemid 350033967)
46. Marangoni F, Angeli MT, Colli S, et al. Changes of n-3 and n-6 fatty acids in plasma and circulating cells of normal subjects, after prolonged administration of 20:5 (EPA) and 22:6 (DHA) ethyl esters and prolonged washout. Biochim Biophy Acta 1993;1210:55-62.
47. Martínez M, Vázquez E, García-Silva MT, et al. Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders1. Am J Clin Nutr 2000;71:376S-85S. (Pubitemid 30046146)
48. Committee for medicinal products for human use. Guideline on clinical trials in small populations European Medicines Agency, London, UK, 2006;1-10.
49. Dallal GE. The Little Handbook of Statistical Practice ebook (kindle edition). USA, 2008.
50. Wang YC, Meyerson L, Tang YQ, et al. Statistical methods for the analysis of relapse data in MS clinical trials. J Neurol Sci 2009;285:206-11.
51. Riccio P. The molecular basis of nutritional intervention in multiple sclerosis: a narrative review. Complement Ther Med 2011;19:228-37.
52. Farinotti M, Simi S, Di Pietrantonj C, et al. Dietary interventions for multiple sclerosis (Review). Cochrane Database Syst Rev 2007(1) CD004192.
53. Marvin MG. Multiple sclerosis review. P T2012;37:175-84.
54. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
55. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
56. Mehta LR, Dworkin RH, Schwid SR. Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis. Nat Clin Pract Neurol 2009;5:82-92.
57. Rafat AS, Saame RS, Laura AS, et al. Omega 3-fatty acids: health benefits and cellular mechanisms of action. Mini Rev Med Chem 2004;4:859-71.
58. Shaikh SR, Edidin M. Polyunsaturated fatty acids, membrane organization, T cells, and antigen presentation. Am J Clin Nutr 2006;84:1277-89. (Pubitemid 44912808)
59. Yao JK. Increased polyunsaturated fatty acids in developing and regenerating peripheral nerve. Biochim Biophy Acta 1982;712:542-6. (Pubitemid 13198982)
60. Lajtha A, Toth J, Fujimoto K, et al. Turnover of myelin proteins in mouse brain in vivo. Biochem J 1977;164:323-29. (Pubitemid 8105668)
61. LeBaron FN, Sanyal S, Jungalwala FB. Turnover rate of molecular species of sphingomyelin in rat brain. Neurochem Res 1981;6:1081-9. (Pubitemid 12213506)